16000354

Source:http://linkedlifedata.com/resource/pubmed/id/16000354

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0020402, umls-concept:C0040028, umls-concept:C0051809, umls-concept:C1707455
pubmed:issue	1
pubmed:dateCreated	2005-7-7
pubmed:abstractText	We conducted a randomized comparison of hydroxyurea with anagrelide in the treatment of essential thrombocythemia.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/16000354-16000360
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0255562
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Aspirin, http://linkedlifedata.com/resource/pubmed/chemical/Hydroxyurea, http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines, http://linkedlifedata.com/resource/pubmed/chemical/anagrelide
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	1533-4406
pubmed:author	pubmed-author:BarefordDavidD, pubmed-author:BuckGeorginaG, pubmed-author:CampbellPeter JPJ, pubmed-author:EastClare LCL, pubmed-author:GreenAnthony RAR, pubmed-author:GriggAndrew PAP, pubmed-author:HarrisonClaire NCN, pubmed-author:ReillyJohn TJT, pubmed-author:RevellPaulP, pubmed-author:United Kingdom Medical Research Council Primary Thrombocythemia 1 Study, pubmed-author:WheatleyKeithK, pubmed-author:WilkinsBridget SBS, pubmed-author:WoodcockBarrie EBE, pubmed-author:van der WaltJon DJD
pubmed:copyrightInfo	Copyright 2005 Massachusetts Medical Society.
pubmed:issnType	Electronic
pubmed:day	7
pubmed:volume	353
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	33-45
pubmed:dateRevised	2008-11-21
pubmed:meshHeading	pubmed-meshheading:16000354-Adult, pubmed-meshheading:16000354-Aged, pubmed-meshheading:16000354-Aged, 80 and over, pubmed-meshheading:16000354-Antineoplastic Agents, pubmed-meshheading:16000354-Aspirin, pubmed-meshheading:16000354-Drug Therapy, Combination, pubmed-meshheading:16000354-Female, pubmed-meshheading:16000354-Follow-Up Studies, pubmed-meshheading:16000354-Hemorrhage, pubmed-meshheading:16000354-Humans, pubmed-meshheading:16000354-Hydroxyurea, pubmed-meshheading:16000354-Leukemia, Myeloid, Acute, pubmed-meshheading:16000354-Male, pubmed-meshheading:16000354-Middle Aged, pubmed-meshheading:16000354-Platelet Aggregation Inhibitors, pubmed-meshheading:16000354-Platelet Count, pubmed-meshheading:16000354-Primary Myelofibrosis, pubmed-meshheading:16000354-Quinazolines, pubmed-meshheading:16000354-Thrombocythemia, Essential, pubmed-meshheading:16000354-Thrombosis
pubmed:year	2005
pubmed:articleTitle	Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
pubmed:affiliation	Department of Haematology, University of Cambridge, and Addenbrooke's National Health Service Trust, Cambridge, United Kingdom.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study